knowledge -WSS

knowledge

author：fashion 2025-10-01 21:39:56 - browse：1663

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Congress must reauthorize a committee to support older Americans

WSS

In key trial, Verve's treatment lowers cholesterol levels in patients

Impact of Dobbs ruling felt at reproductive medicine meeting

FDA gives detailed accounting of AI

STAT Summit: GSK CEO on pharma giant's new direction

FDA's Woodcock to retire early next year

NIH confirmation hearing shows politicization of research

focus

knowledge

explore

Tori Bowie and the unacceptable rates of Black maternal death

Eli Lilly expects to double planned employment in Boston center

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: GSK CEO on pharma giant's new direction

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

PBM reforms clear House panel

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: A CRISPR milestone, biotech mixology

At least 13 dead in Texas as scorching temps continue

Will Ozempic

entertainment

Pharmacists can make shortage drugs, but at what cost?

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Studies point to risks of excluding people with obesity from drug trials

HHS leader on health, climate change and biopharma emissions

Anthos stroke drug appears safer than common blood thinner

Beam Therapeutics to lay off 20% of its staff, re

Wikipedia

knowledge

knowledge

entertainment